What is D&D Pharmatech?
D&D Pharmatech operates as a specialized clinical-stage biotechnology firm that utilizes a decentralized subsidiary structure to advance medical innovation. By partnering with top-tier medical research faculty, the company effectively incubates disease-specific entities, ensuring that each therapeutic program receives focused leadership and scientific oversight. This strategic architecture allows D&D Pharmatech to maintain a lean corporate core while scaling its research capabilities across multiple high-potential therapeutic areas. The company's market position is defined by its ability to translate complex academic discoveries into viable clinical assets, a process that has historically attracted substantial venture and institutional backing.
How much funding has D&D Pharmatech raised?
D&D Pharmatech has raised a total of $198.9M across 3 funding rounds:
Series B
$137.1M
Series C
$51M
Debt
$10.8M
Series B (2019): $137.1M with participation from LB Investment, Smilegate Investment, Octave Life Sciences, InterVest, and Magna Investment
Series C (2021): $51M led by DS Asset Management, Kudos Venture Capital, Korea Investment & Securities, and Praxis Capital Partners
Debt (2025): $10.8M, investors not publicly disclosed
Key Investors in D&D Pharmatech
DS Asset Management
An investment management firm that focuses on deep insights into companies and industries to foster trusted partnerships with clients for mutual growth.
Kudos Venture Capital
A boutique venture capital firm specializing in early-stage healthcare and life science investments, focusing on incubating start-up concepts until they reach self-sustainability.
Korea Investment & Securities
A major financial firm and institutional investor that plays a central role in the Korean capital market, specializing in asset management, investment banking, and IPO leadership.
What's next for D&D Pharmatech?
Looking ahead, D&D Pharmatech is poised to leverage its recent capital influx to transition several key assets into advanced-stage clinical trials. The strategic focus remains on optimizing the development lifecycle of its subsidiary-led projects, with an emphasis on achieving regulatory milestones that enhance long-term shareholder value. As the company navigates the complexities of the global biotech market, the integration of its recent financing will be pivotal in sustaining its research momentum and expanding its footprint in the pharmaceutical sector. Investors will likely monitor the firm's ability to maintain its collaborative research model while scaling operations to meet the demands of late-stage clinical development.
See full D&D Pharmatech company page
